(Q45874428)

English

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose

scientific article published on 8 January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

0 references

Coagulation factor VIII

0 references

0 references

author name string

M Rubinger

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

D Lillicrap

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

G E Rivard

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

J Teitel

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

M Carcao

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

C Hensman

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

I Walker

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

Association of Hemophilia Clinic Directors of Canada

8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

publication date

8 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

14

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

281-286

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

Inhibitors in congenital coagulation disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Inhibitors in haemophilia: clinical aspects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

High-titer inhibitor development in hemophilia A: lack of product specificity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Is the incidence and prevalence of inhibitors greater with recombinant products? No.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Production processes of licensed recombinant factor VIII preparations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2007.01634.X

21 January 2018

Identifiers

10.1111/J.1365-2516.2007.01634.X

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/18194308

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45874428&oldid=2088233199"